Single award · contract
Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (MARV) and Sudan Ebolavirus…
Award ID: 75A50119C00055
A single federal award, with both ends of the trail linked.
$145.4M
Total award value
Award 75A50119C00055 is a contract from the Department of Health and Human Services to Albert B. Sabin Vaccine Institute, Inc. (The), $145.4M obligated, FY2019 to FY2027, for Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (MARV) and Sudan…. The work is performed in District Of Columbia. It is classified as NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)) and PSC AN73 (R&D- Medical: Specialized Medical Services (Advanced Development)). Source
Description
This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (MARV) and Sudan Ebolavirus (Sudv) Disease.
Award details
Award typeContract
PIID75A50119C00055
Action date2019
Period96 mo
Awarding agencyDepartment of Health and Human Services →
Place of performanceDistrict Of Columbia →
CategoryNAICS 541714PSC AN73
Competed?Not recordedSource
Total (exact)$145,378,689
More awards to Albert B. Sabin Vaccine Institute, Inc. (The)
More from Department of Health and Human Services
awarded 2025$110.4B
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.